Do prostate cancer drugs interact with certain anticoagulants to increase bleeding and clotting risks?

Study finds similar safety regardless of anticoagulant type.

2026-03-09

(Press-News.org) In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ bleeding or clotting risks, despite previous lab results that raised alarms. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Thromboembolism, caused by a circulating blood clot that gets stuck and causes an obstruction, is the second leading cause of death in people with cancer, surpassed only by progression of the cancer itself. Anticoagulants (blood thinners) are standard therapy to treat or prevent thromboembolism. For individuals with advanced prostate cancer, thromboembolism can be especially worrisome because lab experiments have indicated that androgen-receptor pathway inhibitors, which are recommended for nearly all patients with advanced prostate cancer, can interact with certain anticoagulants—specifically, direct oral anticoagulants (DOACs).

To investigate whether these lab-based findings correlate to real concerns in patients, researchers evaluated outcomes in patients taking both anticoagulants and androgen-receptor pathway inhibitors, including enzalutamide, apalutamide, and abiraterone.

In the retrospective population-based analysis of 2,997 Canadian adults with prostate cancer who were prescribed anticoagulants (DOACs or non-DOACs) and enzalutamide or apalutamide between 2012 and 2023, investigators found no increased risks of clotting in the DOAC versus non-DOAC groups. Similarly, investigators compared DOAC and non-DOAC groups combined with abiraterone and did not find an increased risk of bleeding.

“As clinicians, we are faced with the question of choosing the best anticoagulant option for patients on a daily basis, and the complexity further increases in patients with cancer taking many other medications including anticancer therapies that could cause concerning drug–drug interactions,” said lead author Tzu-Fei Wang, MD, of the University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute. “Our findings suggest that pharmacokinetic drug–drug interaction concerns may not translate into adverse clinical outcomes in the real world. These results can help clinicians and patients feel more confident when managing anticoagulation alongside modern prostate cancer treatments.”

Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com

Full Citation:
“Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents.” Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont, Cynthia Wu, Pietro Ravani, Dominick Bossé, Robert Talarico, Marc Carrier, and Manish M. Sood. CANCER; Published Online: March 9, 2026 (DOI: 10.1002/cncr.70266).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.70266

Author Contact: Jenn Ganton, Executive Director of Communications and Public Relations at the Ottawa Hospital Research Institute, at jganton@ohri.ca or +1 613-614-5253

About the Journal    
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on X @JournalCancer , and stay up to date with the American Cancer Society Journals on Instagram,  LinkedIn, and YouTube.

About Wiley      
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram. 

END

ELSE PRESS RELEASES FROM THIS DATE:

Many patients want to talk about their faith. Neurologists often don't know how.

2026-03-09

People living with neurological diseases such as Parkinson's disease, dementia and epilepsy face not only physical decline, but also profound questions about identity, purpose, and meaning. Yet physicians best positioned to address those concerns do not have the adequate training and tools to do so, a new paper states. The paper, published in the journal Neurology Clinical Practice by researchers from UCLA Health, the University of Colorado, Harvard Medical School and Brown University, argues that spiritual assessment should become a routine part of neurological care, and offers practical guidance for how clinicians can make it happen. The paper describes why neurologists are uniquely ...

AI disclosure labels may do more harm than good

2026-03-09

The growing use of AI-generated scientific and science-related content, especially on social media, raises important concerns: these texts may contain false or highly persuasive information that is difficult for users to detect, potentially shaping public opinion and decision-making. Several jurisdictions and platforms are moving toward clearer disclosure of AI-generated or AI-synthesised content to protect the public. However, a new study published in JCOM warns that these labels may have the opposite effect of what regulators intend, decreasing ...

The ultra-high-energy neutrino may have begun its journey in blazars

2026-03-09

Three years ago, in the waters of the Mediterranean Sea, the passage of an “ultra-energetic” cosmic neutrino was observed — the most energetic ever detected. The event drew international attention from the scientific community as well as from the media and the public, not least because the origin of this particle — whose energy exceeded that of previously observed neutrinos by more than an order of magnitude — is unknown. A new paper published in the Journal of Cosmology and Astroparticle Physics (JCAP) by the KM3NeT collaboration, which operates the KM3NeT/ARCA detector off the coast of Sicily, suggests ...

Doubling of new prescriptions for ADHD medications among adults since start of COVID-19 pandemic

2026-03-09

New prescriptions for stimulants among adults, largely to treat ADHD, more than doubled since the start of the COVID-19 pandemic, especially in younger adults, found new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251065. In the past, stimulants have been prescribed mainly for pediatric cases of ADHD and some other conditions. However, over the last 20 years, ADHD diagnoses and stimulant prescriptions have increased globally in adults, and data indicate this trend accelerated after the start of the pandemic. Canadian researchers sought to understand whether this trend is evident in Canada and ...

“Peculiar” ancient ancestor of the crocodile started life on four legs in adolescence before it began walking on two

2026-03-09

A “peculiar” ancient relative of the crocodile which experts believe began life on four legs before, in adulthood, it learnt how to walk on just two has been revealed in a new study. Named Sonselasuchus cedrus, this archaic reptile was part of the shuvosaurid group, most of which had an appearance mimicking that of the ornithomimid dinosaurs that it shared the landscape with during Late Triassic time (approximately 225-201 million years ago). In peer-reviewed findings, published today in the Journal of Vertebrate Paleontology, ...

AI can predict risk of serious heart disease from mammograms

2026-03-09

AI can quantify calcification build-up in breast arteries via mammograms. This ‘arterial calcification’ is strongly linked to the risk of heart attack, stroke, and death. Breast cancer screening could also be used to screen for cardiovascular disease. Sophia Antipolis, France – 9 March 2026. The risk of serious or fatal heart disease can be predicted with artificial intelligence (AI) analysis of mammograms, according to research published in the European Heart Journal [1] today (Monday). The study ...

New ultra-low-cost technique could slash the price of soft robotics

2026-03-09

More images available via the link in the notes section Engineers at Oxford University have developed a rapid, ultra-low-cost method for manufacturing soft robots using common lab equipment. The method has been published today (8 March) in Advanced Science. The new technique enables researchers to fabricate soft robotic actuators - the flexible components that power movement - in under 10 minutes at a material cost of less than $0.10 (US Dollars) per unit. Principle Investigator and corresponding author Professor Antonio Forte (Department of Engineering Science, University of Oxford) said: “By lowering the financial and technical barriers ...

Increased connectivity in early Alzheimer’s is lowered by cancer drug in the lab

2026-03-09

Neuroscientists at King’s College London have pinpointed a mechanism behind the increased neural connectivity observed in the very early stages of Alzheimer’s disease. Published in Translational Psychiatry, the study also demonstrated that a cancer medication has the potential to reduce this hyperconnectivity. The research, funded by Alzheimer's Society and conducted in brain cells of rats, showed that low levels of the protein amyloid-beta could induce hyperconnectivity and this pattern closely resembled changes seen in the brains ...

Study highlights stroke risk linked to recreational drugs, including among young users

2026-03-08

The recreational drugs cannabis, cocaine and amphetamines significantly increase the risk of stroke – including among younger users – Cambridge researchers have concluded after analysing data from more than 100 million people. Stroke is a major global health challenge – the third leading cause of death and disability combined. But it also a condition that, for the most part, results from modifiable risk factors, such as poor diet, lack of exercise and other lifestyle factors. In 2024, 8.8% of adults aged 16 to 59 years in England and Wales – around 2.9 ...

Modeling brain aging and resilience over the lifespan reveals new individual factors

2026-03-08

VANCOUVER - March 8, 2026 - Age is more than just one number. While neuroscientists used to think of cognitive aging as a single trendline, they now realize that vast individual differences require a more predictive and personalized approach. As they uncover more factors that affect cognition over time, they are realizing that modeling the aging brain requires more diverse data than traditionally captured. “We need to appreciate that how people age is as much a biological process as it is a social process,” says Randy McIntosh of Simon Fraser University, who is chairing a symposium at the ...

Do prostate cancer drugs interact with certain anticoagulants to increase bleeding and clotting risks?

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: